Eyenovia, Inc. (EYEN)
NASDAQ: EYEN · Real-Time Price · USD
0.0856
+0.0011 (1.30%)
At close: Dec 24, 2024, 1:00 PM
0.0850
-0.0006 (-0.70%)
Pre-market: Dec 26, 2024, 9:06 AM EST
Eyenovia Revenue
Eyenovia had revenue of $1.63K in the quarter ending September 30, 2024, with 35.64% growth. This brings the company's revenue in the last twelve months to $31.83K, up 2,557.10% year-over-year. In the year 2023, Eyenovia had annual revenue of $3.79K.
Revenue (ttm)
$31.83K
Revenue Growth
+2,557.10%
P/S Ratio
147.33
Revenue / Employee
$558
Employees
57
Market Cap
9.54M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Kiora Pharmaceuticals | 16.02M |
Mobile-health Network Solutions | 13.97M |
Evoke Pharma | 8.62M |
Evogene | 7.48M |
Can-Fite BioPharma | 667.00K |
BioCardia | 71.00K |
EYEN News
- 20 days ago - Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering - GlobeNewsWire
- 4 weeks ago - Eyenovia Provides Update on Restructuring Efforts - GlobeNewsWire
- 5 weeks ago - Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline - Benzinga
- 5 weeks ago - Eyenovia to discontinue late-stage study for eye drug - Reuters
- 5 weeks ago - Eyenovia Provides Update on Phase 3 CHAPERONE Study - GlobeNewsWire
- 6 weeks ago - Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th - GlobeNewsWire
- 2 months ago - Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo - GlobeNewsWire